SiBone (NASDAQ:SIBN) Given Average Rating of “Moderate Buy” by Analysts

Shares of SiBone (NASDAQ:SIBN) have earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $24.3333.

A number of analysts recently issued reports on SIBN shares. Needham & Company LLC raised their price objective on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Truist Financial upped their price objective on SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Canaccord Genuity Group boosted their target price on SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. Finally, TD Cowen upgraded shares of SiBone to a “strong-buy” rating in a research note on Tuesday, January 27th.

SiBone Price Performance

Shares of NASDAQ SIBN opened at $15.33 on Friday. SiBone has a 52 week low of $12.49 and a 52 week high of $21.89. The stock has a market capitalization of $665.18 million, a price-to-earnings ratio of -30.06 and a beta of 0.69. The company has a quick ratio of 6.62, a current ratio of 7.97 and a debt-to-equity ratio of 0.21. The firm has a 50-day simple moving average of $18.18 and a 200-day simple moving average of $16.90.

Insider Activity at SiBone

In other news, Director Jeffrey W. Dunn sold 20,000 shares of the company’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $21.28, for a total value of $425,600.00. Following the sale, the director directly owned 80,115 shares in the company, valued at $1,704,847.20. This represents a 19.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Anshul Maheshwari sold 18,542 shares of SiBone stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $20.15, for a total value of $373,621.30. Following the completion of the sale, the chief financial officer directly owned 185,231 shares of the company’s stock, valued at approximately $3,732,404.65. This represents a 9.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 119,918 shares of company stock valued at $2,341,576. Corporate insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On SiBone

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Assenagon Asset Management S.A. lifted its position in shares of SiBone by 0.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 225,001 shares of the company’s stock worth $4,437,000 after buying an additional 997 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in SiBone by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after acquiring an additional 1,053 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of SiBone by 42.3% during the fourth quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock valued at $70,000 after purchasing an additional 1,061 shares during the last quarter. Calamos Advisors LLC raised its position in shares of SiBone by 14.6% during the 4th quarter. Calamos Advisors LLC now owns 11,484 shares of the company’s stock worth $226,000 after purchasing an additional 1,465 shares during the period. Finally, ANTIPODES PARTNERS Ltd bought a new stake in shares of SiBone in the 4th quarter worth approximately $29,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.